Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma

Pranabashis Haldar Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK Abstract: Mepolizumab (Nucala®) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Haldar P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Mepolizumab IL-5 eosinophils asthma exacerbations Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/111bf5d433994f3c93b4a3dfd6b4a85f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:111bf5d433994f3c93b4a3dfd6b4a85f
record_format	dspace
spelling	oai:doaj.org-article:111bf5d433994f3c93b4a3dfd6b4a85f2021-12-02T06:08:49ZPatient profiles and clinical utility of mepolizumab in severe eosinophilic asthma1177-5491https://doaj.org/article/111bf5d433994f3c93b4a3dfd6b4a85f2017-06-01T00:00:00Zhttps://www.dovepress.com/patient-profiles-and-clinical-utility-of-mepolizumab-in-severe-eosinop-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Pranabashis Haldar Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK Abstract: Mepolizumab (Nucala®) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eosinophilic asthma by the US Food and Drug Administration (FDA), European Medicines Agency (EMA; European Union) and more recently National Institute for Health and Care Excellence (NICE; UK). It is one of several molecular therapies in development for this indication and is illustrative of the strategic trajectory for pharmaceutical drug development taken over the past decade in several disease areas. Molecular therapies offer the prospect of improved specificity and effectiveness of biological effect. However, this necessitates a clear understanding of the underlying mechanistic pathways underpinning pathological processes, to inform drug development that yields novel more efficacious treatment options with a better clinical profile than existing agents. For the first time, utilization of molecular therapies in clinical trials is providing a novel in vivo model to characterize the association between specific pathways and clinical disease expression. It is increasingly recognized that asthma exhibits both clinical and pathological heterogeneity. It follows that a one-size-fits-all approach will not be appropriate and cost-effectiveness may only be achieved by identifying responder subgroups. This so-called personalized approach to therapy is being supported by the parallel development of companion biomarkers for clinical application. In this review, the author summarizes the clinical studies, their interpretation and the lessons learnt with mepolizumab that have informed our understanding of the approach to personalized molecular therapy in asthma. Keywords: IL-5, Nucala, exacerbations Haldar PDove Medical PressarticleMepolizumabIL-5eosinophilsasthmaexacerbationsMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 11, Pp 81-95 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Mepolizumab IL-5 eosinophils asthma exacerbations Medicine (General) R5-920
spellingShingle	Mepolizumab IL-5 eosinophils asthma exacerbations Medicine (General) R5-920 Haldar P Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
description	Pranabashis Haldar Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK Abstract: Mepolizumab (Nucala®) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eosinophilic asthma by the US Food and Drug Administration (FDA), European Medicines Agency (EMA; European Union) and more recently National Institute for Health and Care Excellence (NICE; UK). It is one of several molecular therapies in development for this indication and is illustrative of the strategic trajectory for pharmaceutical drug development taken over the past decade in several disease areas. Molecular therapies offer the prospect of improved specificity and effectiveness of biological effect. However, this necessitates a clear understanding of the underlying mechanistic pathways underpinning pathological processes, to inform drug development that yields novel more efficacious treatment options with a better clinical profile than existing agents. For the first time, utilization of molecular therapies in clinical trials is providing a novel in vivo model to characterize the association between specific pathways and clinical disease expression. It is increasingly recognized that asthma exhibits both clinical and pathological heterogeneity. It follows that a one-size-fits-all approach will not be appropriate and cost-effectiveness may only be achieved by identifying responder subgroups. This so-called personalized approach to therapy is being supported by the parallel development of companion biomarkers for clinical application. In this review, the author summarizes the clinical studies, their interpretation and the lessons learnt with mepolizumab that have informed our understanding of the approach to personalized molecular therapy in asthma. Keywords: IL-5, Nucala, exacerbations
format	article
author	Haldar P
author_facet	Haldar P
author_sort	Haldar P
title	Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
title_short	Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
title_full	Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
title_fullStr	Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
title_full_unstemmed	Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
title_sort	patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/111bf5d433994f3c93b4a3dfd6b4a85f
work_keys_str_mv	AT haldarp patientprofilesandclinicalutilityofmepolizumabinsevereeosinophilicasthma
_version_	1718400035519987712

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma

Ejemplares similares